Atea Pharmaceuticals (AVIR) Cash & Equivalents (2019 - 2026)

Atea Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $79.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 33.57% year-over-year to $79.3 million; the TTM figure through Mar 2026 stood at $79.3 million (down 33.57% YoY), while the FY2025 annual figure was $95.7 million, down 78.78% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $79.3 million, down from $95.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $705.5 million in Q1 2022, with the low at $77.3 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $183.3 million (2023), against an average of $279.9 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 78.99% in 2022, then surged 213.59% in 2024.
• Atea Pharmaceuticals' Cash & Equivalents stood at $188.5 million in 2022, then declined by 23.69% to $143.8 million in 2023, then soared by 213.59% to $451.0 million in 2024, then sank by 78.78% to $95.7 million in 2025, then fell by 17.13% to $79.3 million in 2026.
• Business Quant data shows AVIR's Cash & Equivalents at $79.3 million in Q1 2026, $95.7 million in Q4 2025, and $77.3 million in Q3 2025.